Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
J.B. Hunt Transport Services heads into its October 15 earnings release with analysts broadly trimming price targets and the stock down 17% over the past month to $225.93, setting up a rare disconnect between Street conviction and Street valuation.
The analyst moves tell the clearest story this week. Target cuts have been near-universal. JP Morgan's Brian Ossenbeck lowered his target to $287 from $313 on October 5 while keeping an Overweight rating. Truist Securities cut harder, dropping to $235 from $295 with a Hold. Earlier cuts from Susquehanna, UBS, Raymond James, Baird and Bank of America all landed in September, each preserving the rating but pulling the number lower. The sole upgrade in that window came from Citizens, moving to Market Outperform on September 17 with a fresh $300 target. The mean target across the Street now sits at $287.56, roughly 27% above where the stock is trading, a gap wide enough to reflect genuine disagreement about the path back, not just routine calibration. The analyst recommendation factor score ranks in the 98th percentile of the ORTEX universe, meaning the aggregate consensus is as bullish relative to peers as it has been all year, even as individual targets compress.
The bull case centres on intermodal momentum. Q2 2026 intermodal volumes reportedly rose 10% year-on-year, the first double-digit growth since 2016, with Panama Canal constraints and rivals' execution problems pushing freight toward the West Coast and rail. Dedicated Contract Services posted solid margins, and the brokerage unit turned profitable. Bears point to costs running ahead of recoveries: driver pay up roughly $25 million sequentially, a $10 million fuel hit, and a final mile segment whose revenue fell 6% year-on-year. Valuation has de-rated with the price, with the PE multiple down almost five points over the past 30 days to 24.2x and EV/EBITDA compressing to 11.4x. Those are not cheap multiples in a freight cycle where operating leverage is still uncertain, and the EV/EBIT factor score sits in only the 20th percentile.
Positioning in the lending market and options market is quiet, which itself is notable context. Short interest at under 2% of the free float has fallen 38% over the past month, retreating sharply from early September when it ran closer to 3 million shares. Borrow availability is extremely loose at 2,544%, meaning there is no meaningful demand from short sellers to source shares. Cost to borrow is just 0.44%, effectively free. Options traders are similarly relaxed: the put/call ratio of 0.70 is almost exactly in line with its 20-day average of 0.70, with a z-score near zero and no notable skew toward protection. Peer performance this week has been mixed but tilted negative, with WERN off 3.6% and TFII down 5.9% on the week, while XPO bucked the trend with a 3.5% gain.
Retail attention has spiked sharply. The ORTEX alt data layer flags a Wikipedia-views z-score of 4.0 as of September 17, placing JBHT well above its own 90-day history on retail attention. That reading predates the heaviest analyst activity and the sharpest leg of the price decline. With earnings eight days out, that attention has a clear anchor.
The two previous quarterly prints give some calibration for what that event risk looks like in practice. The April 2026 release produced a 3.8% gain on day one and extended to 7.6% over five days. The July 2026 print delivered a 6.2% gain on day one, fading slightly to 4% over the week. Both moves were to the upside, an unusually consistent pattern for a stock sitting in what analysts describe as a near-term cost headwind environment. The October 15 print will be the first test of whether that intermodal volume story can hold against the rising cost base, and whether the Street's cut-and-hold posture was correctly calibrated or too conservative.
See the live data behind this article on ORTEX.
Open JBHT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
